Targovax AS Raises $3.6 Million in Private and Public Support for TG01 Pancreatic Cancer Vaccine Development
6/6/2013 10:01:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
OSLO, Norway--(BUSINESS WIRE)--Cancer vaccine specialist Targovax today announced that it has raised a total of $3.6 million to accelerate development of its RAS mutation-targeted therapeutic cancer vaccine pipeline, specifically lead candidate TG01 for pancreatic cancer. The funds comprise $2.3 million in public support from the Norwegian Research Council’s BIA programme and $1.3 million from existing and new investors, including the Radium Hospital Research Foundation, Algot Invest and Trygve Schiørbeck.
Help employers find you! Check out all the jobs and post your resume.